Natera (NTRA) announced the activation of the NRG Oncology trial, ARCHER, a randomized, phase III study in muscle-invasive bladder cancer. The study is evaluating whether a shorter course of radiation can achieve outcomes comparable to the current standard of care. It prospectively incorporates Signatera, Natera’s personalized, tumor-informed molecular residual disease test, as a pre-specified secondary endpoint.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Puneet Souda’s Buy Rating on Natera Driven by Promising Signatera Trial Results and Market Growth Potential
- GS, BAC, LEN: Billionaire Investor Stanley Druckenmiller Buys Bank and Housing Stocks
- Natera says IMvigor011 bladder cancer trial achieves positive results
- Natera Inc. Reports Strong Growth and Strategic Advances
- Natera’s Strong Growth Potential and Market Leadership Justify Buy Rating